Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Reiterates Buy on Coherent, Maintains $58 Price Target

Needham analyst James Ricchiuti reiterates Coherent (NASDAQ:COHR) with a Buy and maintains $58 price target.
byBenzinga Newsdesk
February 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Needham analyst James Ricchiuti reiterates Coherent (NASDAQ:COHR) with a Buy and maintains $58 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Molecular Instruments Announced The Patents Court Of England And Wales Has Ordered That Two Patents Owned By Advanced Cell Diagnostics, A Bio-Techne Company, Both Be Revoked, Advanced Cell Diagnostics’ Infringement Claims Against Molecular Instruments…

By Benzinga Newsdesk
May 21, 3:21 PM
Molecular Instruments, Inc. announced that the Patents Court of the High Court of England and Wales has ordered: (1) that two patents owned by Advanced Cell Diagnostics, Inc. ((a Bio-Techne group company, NASDAQ:TECH)

TECH